Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NextEdge Admin

08 Nov 2024

3 min 1 sec

MedGenome, a global leader in multiomics and precision medicine, has appointed Dr. Felix Olale as President and CEO and Jennifer Rose as Executive Vice President and Chief Commercial Officer. This strategic leadership expansion aims to propel MedGenome’s growth across North America, aligning with its mission to uncover insights into disease mechanisms, biomarkers, and personalized medicine through advanced multiomics technologies.

Dr. Olale and Rose’s combined expertise will enable MedGenome to deepen partnerships with biopharma companies and academic researchers, expand its market footprint, and advance next-generation multiomic solutions that support drug discovery and precision medicine initiatives. “MedGenome is at the forefront of innovation,” said Dr. Olale, “providing more than multiomics services—we are a collaborative partner unlocking insights into disease biology.”

Based in Foster City, California, in the heart of Silicon Valley, MedGenome US offers a comprehensive suite of multiomic services that span genomics, epigenomics, transcriptomics, and proteomics. MedGenome works closely with clients to address complex challenges in rare diseases, oncology, and genetic disorders, advancing the role of genomics in precision medicine. Jennifer Rose highlighted the pivotal role of genomics, stating, “MedGenome’s global presence, particularly in India, South Asia, Africa, and Latin America, combined with our spatial transcriptomics, single-cell sequencing, long-read technologies, and genomics-driven antibody drug discovery, uniquely positions us to deliver transformative solutions for drug discovery, diagnostics, and personalized therapies.”

Dr. Olale’s new role as CEO follows his position as Chairman of MedGenome’s board, where he played a key role in shaping the company’s strategy. Dr. Amit Kakar of Novo Holdings Asia will now serve as Chairman, with Dr. Vedam Ramprasad leading operations in India. Mahesh Pratapneni, CEO of MedGenome, expressed confidence in the new leadership, stating, “With Felix leading North America and Dr. Ramprasad driving our business in India, we have the team in place to accelerate MedGenome’s growth and expand its global impact.”